Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M032 in Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
NCT02062827Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2013
- Primary completion
- Sep 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of M032 in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) and Gliosarcoma (GS), sponsored by University of Alabama at Birmingham. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Nov 2013; status: completed.
02
Drugs
M032
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02062827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062827.